AEMD
AETHLON MEDICAL INC (AEMD
NASDAQ · Healthcare · Medical - Devices · US
$6.48
−4.42%Sep 18, 2026, 14:22 UTC
Aethlon Medical Inc. shares dropped on Friday, pulling back after surging more than 300% the previous day.
Source:Sep 17, 2026, 12:23 UTC
Halper Sadeh LLC announced it is investigating whether Aethlon Medical, Inc. is obtaining a fair price for shareholders in its merger with North Immunology, Inc.
Source:Sep 17, 2026, 10:30 UTC
An oversubscribed $180 million private placement is expected to fund the combined Aethlon Medical-North Immunology company's operations into the second half of 2028.
Source:Sep 17, 2026, 10:30 UTC
Aethlon Medical entered a definitive all-stock merger agreement with North Immunology to advance North Immunology's lead IL-13 x IL-18 bispecific antibody NOR-101 for atopic dermatitis.
Sep 15, 2026, 12:21 UTC
Aethlon Medical Inc amended the severance terms of CEO James B. Frakes and Chief Medical Officer Steven P. LaRosa, M.D., effective September 11, 2026, to provide lump-sum severance and healthcare continuation payments upon a Change in Control.
Aug 13, 2026, 20:15 UTC
Aethlon Medical reported financial results for its fiscal first quarter ended June 30, 2026, and provided a corporate update on its Hemopurifier program.
Jul 6, 2026, 13:25 UTC
Aethlon Medical priced a follow-on offering of 5,633,009 shares of common stock (or pre-funded warrants) and warrants at a combined public offering price of $0.7101 per share.
Source: